Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Laharie

Showing results (1-10 of 209) with videos related to

Pageof 21
Sort By:
Lancet (London, England)|May 22, 2017
Towards therapeutic choices in ulcerative colitisDavid Laharie
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2022
ReplyDavid Laharie
Digestive Diseases (Basel, Switzerland)|December 23, 2014
Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatmentDavid Laharie
Alimentary Pharmacology & Therapeutics|February 13, 2024
Letter: Should ulcerative colitis be monitored more or less invasively?David Laharie
Alimentary Pharmacology & Therapeutics|February 18, 2021
Editorial: is enteral nutrition back in acute severe ulcerative colitis?David Laharie
Alimentary Pharmacology & Therapeutics|December 15, 2021
Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitisDavid Laharie, Pauline Rivière
Alimentary Pharmacology & Therapeutics|March 12, 2021
Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' replyDavid Laharie, Pauline Riviere
Alimentary Pharmacology & Therapeutics|January 23, 2025
Letter: Toward Intra-Class Switching With JAK Inhibitors?Mathieu Uzzan, David Laharie
Alimentary Pharmacology & Therapeutics|October 5, 2020
Editorial: biologics in the therapy of Crohn's disease-the fog clearsDavid Laharie, Pauline Riviere
Digestive Diseases and Sciences|February 5, 2020
Concise Commentary: Spaced Out-Reducing the Relapse Risk in IBD Patients by Lengthening Dosing Intervals of Anti-TNFsPauline Rivière, David Laharie
Pageof 21

Showing results (1-10 of 209) with videos related to

Sort By:
Pageof 21
Lancet (London, England)|May 22, 2017
Towards therapeutic choices in ulcerative colitisDavid Laharie
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 5, 2022
ReplyDavid Laharie
Digestive Diseases (Basel, Switzerland)|December 23, 2014
Previous cancer and/or lymphoma in patients with refractory IBD--pro: anti-TNF or immunosuppressive treatmentDavid Laharie
Alimentary Pharmacology & Therapeutics|February 13, 2024
Letter: Should ulcerative colitis be monitored more or less invasively?David Laharie
Alimentary Pharmacology & Therapeutics|February 18, 2021
Editorial: is enteral nutrition back in acute severe ulcerative colitis?David Laharie
Alimentary Pharmacology & Therapeutics|December 15, 2021
Editorial: don't forget basic performance measures in the endoscopic assessment of ulcerative colitisDavid Laharie, Pauline Rivière
Alimentary Pharmacology & Therapeutics|March 12, 2021
Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors' replyDavid Laharie, Pauline Riviere
Alimentary Pharmacology & Therapeutics|January 23, 2025
Letter: Toward Intra-Class Switching With JAK Inhibitors?Mathieu Uzzan, David Laharie
Alimentary Pharmacology & Therapeutics|October 5, 2020
Editorial: biologics in the therapy of Crohn's disease-the fog clearsDavid Laharie, Pauline Riviere
Digestive Diseases and Sciences|February 5, 2020
Concise Commentary: Spaced Out-Reducing the Relapse Risk in IBD Patients by Lengthening Dosing Intervals of Anti-TNFsPauline Rivière, David Laharie
Pageof 21